A phase II trial of extended induction galiximab (anti-CD80 monoclonal antibody) plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL).

Trial Profile

A phase II trial of extended induction galiximab (anti-CD80 monoclonal antibody) plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL).

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Galiximab (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jan 2018 Results (n=61) assessing safety of an extended induction schedule of galiximab (G) plus rituximab (R) in untreated follicular lymphoma (FL) were published in the Annals of Oncology.
    • 06 Dec 2016 Pooled retrospective analysis (n=174) of this trial and two other trials (see NCT00553501 and NCT01145495) evaulating effects of early progression of disease was presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 29 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top